Merck KGaA: Surprising decision to move tecemotide forward in phase III

NEUTRAL, Fair Value EUR110 (-4%)

News published on September Wednesday 25, 2013
Share on

Time will tell if Merck is right to keep investing in its investigational therapeutic vaccine tecemotide (last known as Stimuvax) whose phase III START failed to show an OS benefit when results were unveiled earlier this year. From the very beginning it was said that although the trial failed to reach its primary endpoint, subgroups did show a benefit with the drug.


Full report available to subscribers
Please contact marketing@bryangarnier.fr  

The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities